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Abstract  
Malignant mesothelioma (MM) remains a highly deadly malignancy with poor treatment option.  The 
MM cells further promote a highly inflammatory microenvironment which contributes to tumor 
initiation, development, severity, and propagation.  We reasoned that the anti-inflammatory actions of 
mesenchymal stromal cells (MSCs) and further anti-tumor effects of MSCs engineered to over-express 
TNF-related apoptosis inducing ligand (TRAIL) protein (MSC-TRAIL) would effectively inhibit 
mesothelioma growth.  Using a mouse xenograft model of intraperitoneal human mesothelioma, native 
mouse (mMSC) or human (hMSC) MSCs were administered either systemically (IV) or 
intraperitoneally (IP) at various times following tumor inoculation.  Both mMSCs and hMSCs localized 
at sites of MM tumor growth in vivo and decreased local inflammation.  Further, a trend towards 
decrease in tumor burden was observed.  Parallel studies of in vitro exposure of nine primary human 
mesothelioma cell lines to mMSCs or hMSCs demonstrated reduced tumor cell migration.  In contrast 
MSC-TRAIL exposure induced apoptosis of TRAIL sensitive MM cells in vitro and both mouse and 
human MSC-TRAIL significantly reduced the inflammatory tumor environment in vivo.  Moreover 
human MSC-TRAIL administration significantly reduced peritoneal tumor burden in vivo and increased 
tumor cell apoptosis.  These proof-of-concept studies suggest that TRAIL-expressing MSCs may be 
useful against malignant mesothelioma.       
 
 
Key words mesenchymal stromal cell, malignant mesothelioma, mouse model, cell therapy 
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Introduction  
  Malignant mesothelioma (MM) is a devastating malignancy causally associated with exposure to 
asbestos fibers (1).  Development of MM is associated with high levels of local pleural or peritoneal 
inflammation, particularly driven by the innate immune system (2-4).  The long latency of tumor 
development (30-40 years) and the late stage at which most patients are diagnosed contributes to the 
brief median survival rate (12 months) (5).  The most potent currently available regimen, 
cisplatinum/pemetrexed, has only extended survival an additional six months, compared to untreated 
patients or three months compared to patients receiving cisplatinum alone  (6).  Further, the regimen has 
significant toxicities and quality of life remains poor for most patients.  A variety of other therapeutic 
approaches, including radiation, surgery, other drug combinations, immunotherapy, and gene transfer-
mediated interferon-β have not significantly changed overall morbidity and mortality (7).  Therefore 
novel therapies are desperately needed. 
  Mesenchymal stromal cells (MSCs) are a heterogenous population of multipotent adult cells 
originally isolated from bone marrow and now found to be present in a wide range of tissues including 
adipose, placenta, and others (8).  Current data suggests that some populations of MSCs exist as 
pericytes lining blood vessels where they function to modulate local inflammation (9).  Isolated MSCs 
have been intensely studied for use in tissue regeneration and repair particularly in the context of potent 
immunomodulatory effects on the proliferation and function of a wide range of immune effector cells 
(10-14).  This occurs mostly through paracrine release of soluble mediators but increasing evidence 
suggests a wider range of MSC activities involving both release of microsome particles and also direct 
transfer of mitochondria and other intracellular contents through cell-cell bridges (8, 15).  Further, as 
MSCs do not constitutively express critical cell surface antigens involved in immune recognition and 
rejection, non-human leukocyte antigen matched administration of allogeneic MSCs has been 
increasingly investigated in a wide range of clinical immune and inflammatory disorders including graft 
vs host disease, Crohn’s disease, and rheumatoid arthritis (16,  17).  In parallel, a rapidly growing Effects of TRAIL-Expressing MSCs on Mesothelioma 
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number of studies suggest that MSCs, either through innate anti-inflammatory actions, or when 
engineered to express anti-tumor agents, can have significant effects in reducing tumor burden, 
metastatic disease, and tumor associated inflammatory microenvironments (18-25).  However, there are 
only limited investigations of MSC actions in pre-clinical models of MM. 
Tumor necrosis factor related apoptosis inducing ligand (TRAIL) is a naturally occurring protein 
which functions to induce apoptosis by binding to the death receptor proteins expressed primarily on 
malignant cells (26).  MM cell lines exhibit variable levels of susceptibility to TRAIL-induced apoptosis 
and recombinant TRAIL combined with chemotherapy was shown to be more effective in inhibiting 
tumor growth in vitro and in animal models (27, 28).  We therefore reasoned that the anti-inflammatory 
actions of MSCs combined with TRAIL expression might have significant effects on reducing MM 
tumor burden and associated inflammation.  To assess this, we evaluated MSC effects on tumorigenic 
properties of eleven MM cell lines in vitro, and in parallel, the effects of both mouse and human bone 
marrow-derived MSCs and of MSCs engineered to over-express TRAIL on tumor burden and 
inflammatory environment in a xenograft model following intraperitoneal injection of human MM cells 
into severe combined immune deficient (SCID) mice.  Despite lack of adaptive immunity, these mice 
maintain innate inflammatory responses relevant to MM pathogenesis and are thus a good initial model 
for assessing MSC effects on human mesothelioma cells in vivo (2) 
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Materials and Methods  
Cell culture  
Murine and human bone marrow MSCs (mMSCs, hMSCs) were obtained from the Texas A&M 
Stem Cell Core facility.  These cells have previously been extensively characterized for cell-surface 
marker expression and differentiation capacity (14,  29). For localization experiments, MSCs stably 
transduced to express cytoplasmic green fluorescent protein (GFP) were utilized (14, 29).  For TRAIL 
studies mMSCs transfected and selected for constitutive stable expression and hMSCs transduced to 
express doxycycline-inducible human TRAIL protein (hMSC-FLT) were utilized (14, 29).  All MSCs 
were used at passages 7-8.   
  The pleural MM cell lines HMESO and H2373 have previously been described (2, 30).  Seven 
additional previously described human peritoneal MM cell lines HAY, YOU, ROB, ORT, PET, PRO, 
and HEC (28) were generously provided by Dr. Claire Verschraegen (Vermont Cancer Center, 
University of Vermont).  Human pleural MM cell lines CRL-5820 and CRL-5915 are commercially 
available lines from ATCC (31).   
 
In vitro analysis of tumorigenicity 
MSC effect on MM cell tumorigenic properties of proliferation, migration, invasion, cytokine 
production, and anchorage independent growth were assessed as previously described (2).  
 
SCID mouse xenograft model of human malignant mesothelioma 
  All animal procedures were approved by the UVM IACUC and conformed to all appropriate 
institutional and AAALAC standards. A previously established model of intraperitoneal (IP) inoculation 
of human HMESO cells into SCID mice was utilized (2).   In brief, HMESO cells (5x10
6 for 
localization/tumor development experiments, 1x10
6 cells for MSC treatment experiments), in sterile Effects of TRAIL-Expressing MSCs on Mesothelioma 
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saline were injected IP into male, 6 week old Fox Chase SCID mice (Charles River Laboratories, 
Boston, MA) (2, 32). 
  To assess MSC localization to tumors, or effect on the inflammatory microenvironment and 
tumor development, 1x10
6 MSCs or PBS (control) were injected either systemically (tail vein [IV]) or IP 
on day 27, or 7 and 14, respectively, with analysis on day 28.  To assess MSC effects on peritoneal 
inflammation and tumor burden, tumor inoculated mice received IP injections starting day 21, twice a 
week for 3 weeks.  Mice received either control injections of saline (n=6), or 3x10
5 MSCs in the 
following groups:  MSC-Alone - unmodified mMSCs or hMSCs (n=8 each); MSC-Vector cells - 
mMSCs transfected with empty vector pCMV6-XL5 (n=8), or hMSC-FLT cells not stimulated with 
DOX (n=8); MSC-TRAIL cells - mMSC-TRAIL (clone 87) (n=8), or hMSC-FLT cells stimulated for 72 
hrs with DOX (n=8).  Peritoneal inflammation was assessed by measure of peritoneal lavage fluid (PLF) 
total cell counts and differentials and content of inflammatory cytokines (mouse and human) (2, 32). 
Tumor burden was assessed by collection of all tumors, including any small metastatic nodes, with 
detailed examination of the peritoneal and pleural cavity walls and organs (2, 32).  Tumor apoptosis was 
assessed by TUNEL staining.  
 
Statistical analysis 
Data was evaluated by analysis of variance (ANOVA) using the Fishers LSD procedure for 
adjustment of multiple comparisons to the saline treatment groups and considered significant at p≤0.05 
(33).  p-values approaching significance noted in the figures refer to comparisons with saline controls 
only.  
 
  Further details on all experimental approaches are provided in the supplemental methods section.  
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Results 
MSCs affect migration but not proliferation, invasiveness, or anchorage independent growth of 
MM cell lines.   
We initially ascertained that neither mouse nor human MSCs were induced to differentiate by 
MM medium components and were not killed in direct co-cultures with MM cell lines (data not shown).   
The growth rate of the pleural MM cell lines HMESO or H2373 over 4-7 days of Transwell exposure 
was not significantly altered by exposure to soluble mediators from either hMSCs or mMSCs (Figure 
1A).  The proliferation rate of seven additional peritoneal MM cell lines was determined and categorized 
as either robust, moderate, or weak (Supplemental Figure 1A).  Proliferation of the robust group HAY 
and ORT cells was not changed during Transwell exposure to MSC soluble mediators over days 4-7 
(Supplemental Figure 1B).  Both mMSCs and hMSCs significantly inhibited the migration capacity of 
the four most migratory MM cell lines (HMESO, H2373, CRL5820, and CRL5915), following 
Transwell exposure for 5 days (Figure 1B).  Assessment of six other cell lines, HAY, HEC, ORT, ROB, 
YOU, and PET, demonstrated that HAY and HEC were significantly inhibited only by mMSCs and 
hMSCs, respectively, while the other lines did not migrate sufficiently to determine an impact by MSCs 
(Supplemental Figure 1C).  All 11 cell lines exhibited only weak ability to invade across a basement 
membrane and no effect of exposure to either mMSC or hMSC by Transwell exposure was observed 
(Figure 1C, Supplemental Figure 1D).  Culture of the 11 MM cell lines in anchorage independent 
growth assays identified that only six of the cell lines were capable of growing colonies of significant 
size over 14 days (data not shown).  MSCs inoculated alone into the culture system did not proliferate or 
form colonies and thus did not appear to contribute to the number of colonies observed (Figure 1D).  
Co-plating an equal number of MSCs with the HMESO cells determined that there was no change in the 
size or morphology of colonies formed, and the number of live cells was unaltered (Figure 1D).  These 
combined data indicated that exposure to MSCs does not apparently increase the tumorigenicity of MM Effects of TRAIL-Expressing MSCs on Mesothelioma 
9 
cells.  Conversely, release of the soluble cytokines TNF-α, RANTES, and Interleukin-10 by MSCs was 
not affected by in vitro exposure to the 11 MM lines tested (Supplemental Figure 1E).  
 
MSCs home to MM tumors and alter the tumor microenvironment in SCID mice.  
To assess whether MSCs would localize to MM tumors in vivo, HMESO tumor-bearing SCID 
mice were treated (day 28) with mMSC-GFP cells administered by either IP or IV routes 
(Supplemental Figure 2A).  Mice were harvested 24 hrs later, and the tumors qualitatively assessed for 
presence of MSCs by immunofluorescent staining.  Two types of intraperitoneal tumors result in this 
model: small free floating spheroid tumors and tumors attached to the peritoneal mesentery (2, 32).  
mMSCs were found in both types of tumors, regardless of tumor size and route of administration, both 
at the periphery and within the tumor itself (Figure 2).  No mMSCs were observed within or along the 
periphery of the intestines or other abdominal organs (Supplemental Figure 2B-C).  There was no 
obvious macroscopic evidence of tumor metastasis outside of the peritoneal cavity in other organs 
evaluated including lung, heart, and testes, therefore we did not assess for the presence of MSCs by 
microscopy in other organs.  Although the number of MSCs that localized to the peritoneal tumors was 
not quantitated, these results parallel those observed with MSC localization to tumors in a number of 
other models (22).  Future studies will assess quantitative MSC localization to the inoculated tumors as 
we further optimize the dose and dosing regimen in this model.  
The peritoneal lavage fluid (PLF) was also assessed in these initial localization studies for 
changes in cytokines and chemokines reflecting the inflammatory microenvironment mediated by innate 
immune cells present in the SCID mice (Supplemental Figure 2D).  IP mMSC administration 
significantly reduced PLF levels of mouse KC, IL-12(p70), and TNF-α whereas only TNF-α was 
significantly reduced following IV administration.  Levels of tumor origin human cytokines IL-8, 
VEGF, and MCAF were decreased following IP mMSC administration, however IV administration had 
no effect (Supplemental Figure 2D).  There was no change in total inflammatory cell numbers Effects of TRAIL-Expressing MSCs on Mesothelioma 
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(macrophages, neutrophils, eosinophils) following mMSC administration but a non-significant trend 
towards an increased percentage of neutrophils was observed in the mMSC treated mice (Supplemental 
Figure 2E). 
  Even in the limited immune responsiveness context of a Fox Chase SCID mouse, increased 
inflammation has been closely associated with MM tumor development, with the greatest peritoneal 
inflammation occurring on days 7 and 14 following tumor inoculation (2,  34).  To assess 
immunomodulatory effects and any potential effects on tumor burden if MSCs were administered during 
this period, tumor-inoculated mice received IP administration of mMSCs on days 7 and 14 and were 
subsequently assessed on day 29 (Figure 3A).   A trend towards reduction in mesenteric but not 
spheroid tumor burden was observed (Figure 3B). There was no obvious difference in the overall 
localization of mesenteric or spheroid tumors within the abdominal cavity. Levels of PLF mouse 
cytokines were not significantly changed compared to saline treated mice, but a non-significant trend 
towards decreased levels of human MCAF and VEGF was observed (Figure 3C).  There was no 
significant change in total PLF cell counts but a significant increase in percentage of neutrophils and a 
decrease in percentage of macrophages were observed, with no differences observed in the eosinophil 
population (Figure 3D). 
 
TRAIL expressing MSCs induce MM cell apoptosis in vitro. 
Human TRAIL protein expression on the mouse MSC cell surface was confirmed by flow 
cytometry, following transfection, clonal selection, and assessment of differentiation potential (data not 
shown).  As previously described, treatment of the human MSC-FLT cells with 10µg/mL of DOX for 72 
hrs induces TRAIL expression at the cell surface (21).  This expression once induced remains at high 
levels for an additional 72 hours without further stimulation, before tapering off (21).  
Previous microarray analysis of MM lines HMESO and H2373 identified that HMESO cells 
express TRAIL ligand receptors (Shukla, unpublished data).  Specifically, mRNA was present at Effects of TRAIL-Expressing MSCs on Mesothelioma 
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moderate levels for both the apoptosis-inducing death receptors DR4 and DR5 and also the decoy 
receptor DcR2.  Screening the MM cell lines following 24 hour exposure to recombinant human TRAIL 
protein (rhTRAIL) identified weakly sensitive (HMESO, H2373, HAY) and moderately sensitive (ORT, 
YOU) MM cells (data not shown).  The effectiveness of MSC-TRAIL cells to induce apoptosis was 
subsequently examined on two selected MM cell lines, HMESO (weakly sensitive) and YOU 
(moderately sensitive).  The MSCs were labeled with a cell tracker dye (CMAC) for these studies and 
thus the MSC and MM populations were easily distinguished by flow cytometric gating.  This allowed 
determination of the percent of early apoptotic, late apoptotic, and dead MM cells following exposure to 
MSC-TRAIL cells (Figure 4A).  Direct co-culture for 24 hrs with MSC-TRAIL cells (either human or 
mouse), increased the percentage of HMESO and YOU cells that were apoptotic (Annexin-V positive) 
when compared to control cell lines and positive controls (exposure to 2µg recombinant human TRAIL).  
HMESO cells were more resistant to hMSC-TRAIL induced apoptosis, just approaching significance 
(Figure 4B), while both clones of mMSC-TRAIL cells induced significant increases in the percent of 
apoptotic cells (Figure 4B).  YOU cell apoptosis was significantly increased when cultured with hMSC-
TRAIL cells (Figure 4C), and also when treated with mMSC-TRAIL clone 87 (clone 49 approached 
significance) (Figure 4C).  MSC-Vector cells also increased apoptotic cell number, though not at the 
significant levels observed in the TRAIL expressing cells, but greater than that in control exposures 
using recombinant human TRAIL protein itself (Figures 4B, C).  These data indicate that MSCs alone 
elicit a modest pro-apoptotic effect, through as yet unclear mechanisms.  However, expression of 
TRAIL further increases apoptosis of the tumor cells.  
  
Intraperitoneal administration of either mMSC-TRAIL or hMSC-TRAIL significantly decreases 
peritoneal inflammation, and hMSC-TRAIL further decreases tumor burden. 
  Modification of the xenograft model by administering only 1x10
6 HMESO cells on day 0 results 
in a slower tumor development.  Starting at 21 days after HMESO inoculation, mice received IP Effects of TRAIL-Expressing MSCs on Mesothelioma 
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administration of 3x10
5 mouse or human MSCs, with and without TRAIL expression, twice a week for 3 
weeks. Levels of peritoneal inflammation and of tumor burden were subsequently examined at day 46 in 
comparison to saline-treated controls (Figure 5A, Supplemental Figure 3A).  mMSC-TRAIL 
administration (clone 87) had no significant effect on tumor burden (Supplemental Figure 3B).  There 
was no change in the percent of different inflammatory cell components within the PLF, however a 
significant reduction in the PLF total neutrophil count was observed in mMSC-Vector and mMSC-
TRAIL treated mice (Supplemental Figure 3C).  Administration of mMSC-Alone significantly reduced 
PLF levels of mouse IFN-γ and approached significance in MIP-1α, while mMSC-Vector and mMSC-
TRAIL administration significantly reduced MIP-1α but only approached significance in IFNγ 
(Supplemental Figure 3D).  A non-significant overall trend toward reduced levels of mouse IL-1rα, IL-
2, Eotaxin, KC, MCP-1 (MCAF), and TNFα was observed following administration of mMSC-Alone, 
mMSC-TRAIL, or mMSC-Vector cells.  Significant reductions, compared to saline control, were found 
in PLF levels of human IL-1rα, IL-1β, IL-15, Basic FGF, GM-CSF, MIP-1α, and RANTES following 
administration of mMSC-Alone or mMSC-TRAIL (Supplemental Figure 3E).  Levels of human IL-10 
and VEGF exhibited a non-significant trend towards decrease.  Administration of mMSC-Vector cells 
produced similar but non-significant trends towards decrease in levels of these cytokines.  No significant 
changes occurred in human TNF-α for any treatment group.  Comparison of mMSC-TRAIL 
administration to control cell lines mMSC-Alone or mMSC-Vector showed a synergistic effect of the 
combinatorial MSC+TRAIL administration only in reducing levels of IL-1rα when compared to MSC-
Vector (Supplemental Figure 3E).  Sections of tumor were analyzed for levels of apoptosis by staining 
for TUNEL. Compared to saline controls in which minimal TUNEL staining was observed, tumors from 
mice treated with either mMSC-Alone or mMSC-TRAIL cells exhibited increased levels of TUNEL 
positive cells (Supplemental Figure 3F).   
In contrast to mMSC-TRAIL, TRAIL-expressing hMSCs significantly reduced tumor burden 
compared to saline controls (Figure 5B).  Administration of hMSC-Alone or hMSC-Vector cells also Effects of TRAIL-Expressing MSCs on Mesothelioma 
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produced a trend towards reduced tumor burden, but this was not significant compared to saline 
controls.  However, the hMSC effect on tumor burden (either Alone or Vector control) was such that the 
comparison of MSC-TRAIL to either control group was not additionally significant.  hMSC 
administration (Alone, Vector, and TRAIL) significantly increased the percentage of neutrophils within 
the PLF cell population (Figure 5C) but had no significant effect on the number of total inflammatory 
cells.  Levels of murine CD45 mRNA expression, an index of infiltrating inflammatory cells in the 
tumors, was not altered in any group examined compared to saline controls (data not shown).  Minimal 
TUNEL staining was observed in saline controls, while in comparison, tumors from mice treated with 
either hMSC- Alone or hMSC-TRAIL cells exhibited increased levels of TUNEL positive cells (Figure 
5D), with the greatest levels observed in hMSC-TRAIL treated tumors, indicating that the reduction in 
tumor burden was correlated with an increase in apoptosis within the tumors.   
  hMSC administration further significantly decreased levels of multiple PLF cytokines and 
chemokines, both mouse and human in this model.  Administration of hMSCs (all groups) significantly 
reduced the levels of mouse IL-2, IL-3, IL-10, IL-12(p70) (excluding hMSC-Vector), GM-CSF, MIP-
1β, and TNF-α (Figure 6A).  hMSC-TRAIL treatment also significantly reduced mouse IL-1β, and IL-
13, while hMSC-Alone treatment significantly reduced mouse IL-4, and IL-17.  Levels of IFN-γ were 
reduced in every category (hMSC-Alone was not analyzed as only a single data point was above the 
level of detection) (Figure 6A).  Comparison of hMSC-TRAIL administration to hMSC-Alone or 
hMSC-Vector showed a synergistic effect of the combinatorial MSC+TRAIL in reducing levels of 
mouse GM-CSF, and TNF-α when compared to MSC-Vector, and in TNF-α when compared to MSC-
Alone (Figure 6A). 
  Significantly reductions were observed in PLF levels of human IL-1β, IL-10, IL-12(p70), MCP-
1(MCAF), RANTES, TNF-α, and VEGF were observed following hMSC-TRAIL administration, while 
hMSC-Alone and hMSC-Vector had minimal impact (Figure 6B).  Comparison of hMSC-TRAIL to 
controls showed that the combinatorial MSC+TRAIL administration was significant in reducing levels Effects of TRAIL-Expressing MSCs on Mesothelioma 
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of IL-1β, IL-10, RANTES, and TNF-α when compared to hMSC-Alone.  However, the trend towards 
reduction in hMSC-Vector resulted in no significant differences when compared to hMSC-TRAIL 
(Figure 6B). 
In parallel with the earlier studies, hMSC administration resulted in a significant reduction in the 
PLF mouse and human TNF-α (Figure 6A, B), whereas mMSC administration significantly reduced 
mouse but not human TNF-α in the 24 hr co-localization study (Supplemental Figure 2D).  The same 
trend was observed in mouse but not human TNF-α following mMSC administration (Supplemental 
Figure 3D, E).   Effects of TRAIL-Expressing MSCs on Mesothelioma 
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Discussion 
Following systemic or intraperitoneal administration, otherwise unmodified mouse or human 
MSCs could be located in tumors and decreased peritoneal inflammation in an in vivo mouse xenograft 
model of human mesothelioma tumorigenesis.  In parallel in vitro studies, mouse and human MSCs 
inhibited migration of multiple MM cell lines following in vitro exposure but did not affect other 
tumorigenic properties.  Conversely, conditioned media from MSC/MM cell line Transwell exposure did 
not significantly alter cytokine release from MM cells, mMSCs, or hMSCs.  Administration of mMSCs 
or hMSCs over-expressing human TRAIL significantly reduced inflammation and while hMSCs alone 
or transduced with an empty vector produced a trend towards decreased tumor burden, administration of 
hMSC-TRAIL significantly reduced tumor burden.  Administration of mMSCs or hMSCs, regardless of 
TRAIL expression, increased tumor apoptosis compared to controls. These results suggest a potential 
role of MSCs and in particular TRAIL-expressing hMSCs in therapeutic approaches for MM.      
  A rapidly growing literature demonstrates the effectiveness of MSC-based therapy approaches in 
a variety of pre-clinical inflammatory disease models (35).  There are a growing number of clinical trials 
of MSC therapy in inflammatory and immune based diseases (www.ClinicalTrials.gov), including recent 
approval for MSC use in severe refractory pediatric graft vs host disease in Canada (36).  Importantly, 
there have been no significant safety concerns or adverse events on follow up in these inflammation-
focused trials (37,  38).  These findings suggest that MSC-based cell therapy approaches may be 
particularly appealing for some cancer therapies, though the impact of immunosuppression in cancer and 
the possible contribution of MSCs to surrounding stroma in some types of cancers (35) will require 
continued study.  Notably MSCs home to areas of both primary and metastatic tumors, through 
chemotactic pathways still being elucidated (11).  MSCs can also alter the tumor microenvironment and 
decrease inflammation, an important potential therapeutic effect for inflammatory tumors such as MM 
(39) (40, 41).  Other studies have described this innate MSC anti-tumorigenic effect in a number of 
cancer models (35) thus establishing a potential role for MSCs as non-immunogenic cell based cancer Effects of TRAIL-Expressing MSCs on Mesothelioma 
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therapy.  Further, a growing literature suggests that engineered MSCs may be even more potent anti-
tumor agents.  MSCs have been transfected or transduced with recombinant viral vectors to express anti-
tumor compounds including Bcl-2 and TRAIL (18-20,  22-25).  In particular, recombinant viral 
transduction of MSCs with human TRAIL has been shown to effectively inhibit in vivo progression of 
lung cancer (22), as well as a variety of primary and metastatic tumors including glioma and breast 
carcinoma (21, 25), (19).  MSC-TRAIL also suppressed proliferation of pancreatic cancer lines in vitro 
(23) and overcame TRAIL resistance in in vivo colorectal cancer models (24).  Combination of a 
dodecameric TRAIL vector combined with MSCs engineered to over-express the suicide gene HSV-tk 
was able to completely inhibit metastatic renal cell carcinoma in a pre-clinical model (20). 
                With  respect  to  MM,  recombinant TRAIL peptides have been demonstrated to induce 
apoptosis in several MM cell lines (27).  A recent study demonstrates that the same TRAIL-expressing 
hMSCs used in this study were able to reduce tumor burden in a xenograft model of human 
mesothelioma cells inoculated into the pleural cavity (42) .  This study further extends and corroborates 
those initial findings in a peritoneal model.  The current study also includes detailed assessments of 
MSC effects on the pro-inflammatory peritoneal environment produced in the xenograft model.  Our 
data confirms the induction of MM cell apoptosis observed in vitro when treated with MSCs alone or 
expressing TRAIL (42), and further determines the effects of MSCs alone on MM tumorigenesis using 
standard in vitro assays, aspects which had not previously been assessed in the pleural study.   
Acknowledging the limitations of assessing inflammatory pathways in immunocompromised 
SCID mice, innate immune responses are maintained and there were a number of intriguing findings.  
Both unmodified and modified MSCs altered the tumor microenvironment through both the reduction in 
soluble inflammatory mediators, and inducing a shift in the peritoneal inflammatory cell profile.  Both 
of these actions may affect pro- and anti-tumorigenic pathways (43, 44).  As MM is a highly 
inflammatory tumor, and local inflammation is postulated to contribute to both MM survival and 
proliferation (39, 45), this may be a significant mechanism by which MSC-based therapy could impact Effects of TRAIL-Expressing MSCs on Mesothelioma 
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clinical MM.  As such, these hypothesis-generating observations will be further explored in syngenic 
immunocompetent allograft models of mouse MM (46).  Nonetheless, our findings are in keeping with 
many observations demonstrating the ability of MSCs to decrease inflammatory tumorogenic 
environments (11, 13).   
  We also found that membrane bound human TRAIL-expression on either human or mouse 
MSCs induced apoptosis in multiple human MM cell lines in vitro.  Notably, there can be differences in 
actions of MSCs obtained from mice vs human and soluble anti-inflammatory cytokines released by 
human MSCs may not be appropriately recognized by murine inflammatory, immune, and other relevant 
effector cells.  Thus, as the overall goal is to develop a strategy for use of human MSCs in 
mesothelioma, it was important to include both in these initial studies.  Importantly, use of human 
TRAIL-expressing hMSCs in the in vivo model resulted in a significant decrease in tumor burden as 
well as in inflammation.  Although hMSCs alone or hMSCs transduced with an empty vector produced 
trends towards decreased tumor burden, only the TRAIL-expressing hMSCs produced significant 
decreases compared to saline controls.  As treatment with recombinant TRAIL (which has a limited half 
life around 30 min (42)) did not significantly increase apoptosis in vitro (Figure 4) we did not include 
an arm in which recombinant TRAIL peptide alone was administered, but this will be included in future 
larger scale studies.  In some cases synergistic decrease in inflammatory cytokines were observed 
compared to administration of non-TRAIL expressing MSC controls.  In contrast, mouse TRAIL-
expressing MSCs decreased inflammation but had no significant effect on tumor burden.  The 
transfected mouse MSCs constitutively express human TRAIL while the transduced human MSCs are 
induced with DOX, and this induction results in very high expression for 3-4 days, before tapering off.  
Therefore two doses a week were given to achieve and maintain consistent expression.  Identifying 
whether the potential difference in MSC dose, quantitation of MSC localization to tumor, or species-
difference of the MSCs is the key factor in the different results observed will need to be examined in 
future larger scale studies.  Notably, both mouse and human MSCs, regardless of TRAIL expression, Effects of TRAIL-Expressing MSCs on Mesothelioma 
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stimulated tumor apoptosis but had no significant effects on the number of infiltrating leukocytes.  These 
initial findings will be more extensively explored in future studies, including those in immunocompetent 
mouse allograft MM models.  As these results parallel a number of similar results following 
administration of MSCs in other cancer models, we did not include an arm with a control (non-MSC) 
cell line in these initial studies but will do so in future investigations.   
  Recent data suggests that one potential anti-tumor action of MSCs is through TNF-α signaling.  
In the context of high levels of NF-κB, TNF-α functions as a pro-survival signal (47), a trait observed in 
many MM tumor lines (1, 5, 39).  Notably, MSC secretion of TSG-6 can inhibit NF-κB signaling (48), 
while macrophages co-cultured with MSCs exhibited lower TNF-α (49), and TNF-α stimulation of 
MSCs activated innate TRAIL levels (50).  In the current studies, depending on the model utilized both 
mMSCs and hMSCs suppressed TNF-α levels, MSC-TRAIL treatment synergistically reduced these 
levels, and the consistent reduction of both mouse and human TNF-α correlated with the reduction in 
tumor size observed in hMSC-TRAIL therapy.  This suggests that inhibition of TNF-α may be a means 
of breaking the pro-survival signal to allow apoptosis to occur, as seen in the TUNEL staining, and the 
addition of TRAIL at high levels induces further apoptosis, sufficient to inhibit tumor development.  
Investigation of TNF-α knockdown in combination with MSC therapy will be a key element of future 
studies analyzing the mechanism of MSC function.   
The 25% reduction in tumor burden observed in the HMESO xenograft MM model, with its high 
inflammation and only poor-moderate TRAIL-sensitive status, suggests a significant and potentially 
clinically relevant MSC impact within the constraints of this model.  In addition, as inflammation is 
critical to the pathogenesis, evolution, and maintenance of MM tumors, decrease in inflammatory 
parameters, even within the constraints of the SCID model utilized suggestive further potential clinical 
utility of MSC administration in MM (46, 51).  Therefore these proof-of-concept studies set the 
groundwork for more extensive future investigations, while highlighting the potential of MSCs as a 
potential co-therapy for MM. Effects of TRAIL-Expressing MSCs on Mesothelioma 
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Figure Legends 
Figure 1.  MSCs inhibit the tumorigenic properties of malignant mesothelioma cell lines in vitro. 
A) Transwell exposure of HMESO or H2373 (Black Circles) cells to either hMSC or mMSC cells 
(White Squares) did not alter the proliferation profiles over 4 to 7 days.  Cell counts are calculated based 
on independently grown standard curve of MM cells.  Experimental replicates=3, data presented as total 
cell number (mean +/- Std Dev).  B) MSCs inhibit the migration capacity of the more migratory MM 
cell lines – HMESO, H2373, CRL-5820, and CRL-5915, following Transwell exposure to the MSCs for 
5 days. N=3, data presented as intensity of crystal violet stain, OD595 (mean +/-SEM).  C) Invasion 
across a basement membrane is not affected by 5 days MSC Transwell exposure, n=3, data presented as 
intensity of crystal violet stain, OD595 (mean +/-SEM).   D) Representative images demonstrating that 
anchorage independent colony formation by HMESO cells is not altered when MSCs are present in the 
agar, with quantification of live cells by MTT assay. n=3 independent colony formation assay platings.  
Original Mag 4X.  Significance as determined by ANOVA with a Fishers LSD post-test was indicated 
on each graph as p≤0.05=*, p≤0.01=**, p≤0.001=***.  
 
Figure 2.  mMSC-GFP cells are present within spheroid and mesenteric tumors at 24 hrs following 
systemic or localized administration. 
Representative confocal fluorescence microscopy images from 2-4 images scored per tissue, from three 
mice per injection group.  Original Mag 40X, Scale bar indicates 50μm. Arrows indicate MSCs. 
  
Figure 3.  Intraperitoneal administration of mMSCs alter the tumor microenvironment but not 
the tumor burden. 
A) Schematic of MSC treatment during tumor development experiment protocol. B) Examination of the 
tumor burden (examined here as the average tumor weight per mouse) in mice treated IP with mMSC 
cells on day 7 and 14 resulted in a trend toward a reduction in average mesenteric tumor weight. n=7 Effects of TRAIL-Expressing MSCs on Mesothelioma 
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Saline control (White bars), n=8 MSC IP (Grey bars), data presented as average tumor weight per mouse 
(mean +/-SEM).  C) Bioplex analysis of mouse and human soluble inflammatory cytokines within PLF 
in the early treatment model identified only a trend in reduction in two human cytokines (MCAF and 
VEGF). Units are pg/mL (mean +/-SEM).  D) Differential cell counts of PLF fluid from the early 
treatment model identified a significant increase in the percent of neutrophils within the PLF, but no 
significant change in the PLF total cell count.  Percentage or cell count presented (mean +/-SEM). 
Significance compared to saline control is indicated as p≤0.05=*, p≤0.01=**, p≤0.001=***. 
 
Figure 4.  MSC-TRAIL cells induce apoptosis in MM cell lines in vitro.  
A) Flow cytometry schematic.  Total cell population was examined by side scatter and Cell Tracker 
Blue (CMAC - in the DAPI channel). Top two panels: Y-axis – side scatter, X-axis - CMAC 
fluorescence intensity).  CMAC negative cells were examined for Annexin V (PE) (Y-axis) and 
Viability (7-AAD) (X-axis).  Bottom panels: all axis are fluorescence intensity.  The percent of Annexin 
V positive, 7-AAD negative cells was presented as fold change normalized to untreated cells (n=3 
experimental replicates, mean +/- SEM). B) HMESO cells cocultured for 24 hrs with MSCs show an 
increased percent of apoptotic cells.  C). YOU cells cultured as above also exhibit increased apoptotic 
cell numbers.  MSC-Vector cell (mouse or human) treatment of either MM cell line results in a modest 
increase that does not reach significance.  Significance as determined by ANOVA with a Fishers LSD 
post-test, when compared to MM cells alone (untreated) is indicated as p≤0.05=*, p≤0.01=**.   
 
Figure 5.  TRAIL-expressing hMSCs inhibit tumor growth when administered intraperitoneally to 
mature tumors.   
A) Schematic of MSC treatment during tumor development experiment protocol. B) Group average of 
sum tumor burden per mouse in g (mean +/-SEM). hMSC-TRAIL administration significantly reduced 
the total weight of tumors, with hMSC-Alone and hMSC-Vector administrations showing modest Effects of TRAIL-Expressing MSCs on Mesothelioma 
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reductions. Average tumor burden and the distribution of tumor burden on a per mouse basis are 
indicated. C) Differential cell populations from within the PLF, data presented as average percent or 
total cell count (mean +/-SEM). D) Representative images demonstrating positive TUNEL staining of 
large numbers of tumor cells (yellow-brown) following administration of either mMSC-Alone, hMSC-
Alone, mMSC-TRAIL, or hMSC-TRAIL, compared to control. Original magnification 20X, scale bar 
indicates 200μm. n=5 Saline control, 8 hMSC-Alone, 7 hMSC-Vector, and 8 hMSC-TRAIL.   
Significance as determined by ANOVA with a Fishers LSD post test, compared to Saline control is 
indicated as p≤0.05=*. 
  
Figure 6.  hMSC-TRAIL cell therapy alters soluble cytokines of the tumor microenvironment.  
Bioplex analysis of soluble inflammatory cytokines within PLF of mice therapeutically treated with 
hMSCs identified significant reductions in A) mouse and B) human soluble cytokines.  All units are 
pg/mL (mean +/-SEM); histogram colors: Saline control: White, mMSC-Alone: Light Grey, mMSC-
Vector: Dark Grey, mMSC-TRAIL: Black.   n=5 Saline control, 8 hMSC-Alone, 7 hMSC-Vector, and 8 
hMSC-TRAIL.  Significance as determined by ANOVA with a Fishers LSD post-test is indicated as 
p≤0.05=*, p≤0.01=**, p≤0.001=*** with respect to saline levels.  Significant changes between hMSC-
TRAIL treatment and hMSC-Alone or hMSC-Vector are indicated by the symbols # and @ respectively, 
and significance is indicated as p≤0.05 level only.  The addition of p-values approaching significance in 
the figure represent comparison to saline controls only.  Effects of TRAIL-Expressing MSCs on Mesothelioma 
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Supplemental Figure Legends 
Supplemental Figure 1. MSC effects on MM cell lines shows consistency across multiple cell lines. 
MSC ability to inhibit tumorigenic properties was examined in 11 cell lines, HMESO, H2373, HAY, 
HEC, ROB, YOU, PET, PRO, ORT, CRL-5820, AND CRL-5915.  A) Initial proliferation 
characterization of the 7 peritoneal cell lines identified 3 groups with different proliferation ability.  
Experimental replicates n=3, data presented as cell number (mean +/-Std Dev).  PRO proliferation was 
so low it was examined for each assay once, and not used for subsequent experimentation.  B) Based on 
the robust nature (relative to the other 5 peritoneal lines, but still drastically lower than the other 4 lines 
used) HAY and ORT were tested for the effect of MSC Transwell exposure over days 4-7 of cell 
growth. n=3, data presented as calculated cell number (mean +/-Std Dev).  C) Migration was examined 
in all 11 cell lines, with PRO excluded after a single trial.  n=4, data presented as crystal violet intensity 
by OD595 (mean +/-SEM) normalized to an equally stained, empty Transwell background level. D) 
Invasion was examined in all cell lines once, and repeated in HMESO H2373, CRL-5820, CRL-5915, 
HAY, HEC, ROB, YOU and ORT.  n=4 data presented as crystal violet intensity by OD595 (mean +/-
SEM) normalized to an equally stained, empty Transwell background level. E) Bioplex analysis of MSC 
cytokine expression in Transwell culture supernatants at day 6.  Clusters of three bars are colored per 
MM cell line exposed to, in all cases the left bar is levels produced by MM cell line alone, the center bar 
(over label tick mark) indicates hMSC Transwell exposure (cytokines produced by both MM and hMSC 
cells), and the right bar indicates mMSC Transwell exposure. All units are pg/ml (mean +/- SEM). 
Significance as determined by ANOVA with a Fishers LSD post test, in comparison to medium alone is 
indicated as p≤0.05=*, p≤0.01=**, p≤0.001=***. 
 
Supplemental Figure 2.  MSCs alter the tumor microenvironment and MSCs localize to the site of 
MM tumor growth and are not observed on intestines at 24 hrs. Effects of TRAIL-Expressing MSCs on Mesothelioma 
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A) Schematic of localization experiment protocol.  B) mMSC-GFP cells are not observed in intestinal 
tissues from tumor bearing mice (n=3 mice per group, tumor and intestine blocks).  Staining of paraffin 
embedded sections using an anti-GFP-Alexa-555 conjugated antibody, following antigen retrieval.   
Staining controls from a WT C57Bl6 mouse, and a ubiquitous GFP (C57Bl6 CMV-GFP) mouse were 
used to identify antibody specificity and function. Auto-fluorescence in the red channel (arrows) was 
observed in the enterochromaffin cells in all intestines examined.  GFP fluorescence was never observed 
to co-localize with the auto-fluorescence of the enterochromaffin cells.  The tissue section of WT gut 
shown was proximal to inner surface so none is seen in this image.  Overlap of the Alexa-555 and GFP 
fluorescence is considered positive for mMSC-GFP cells.  Intestine sections from mice treated IV with 
mMSC-GFP cells identified no positive staining for MSC cells, as shown here (bracket) nor in any 
region examined.  The interior of mesenteric tumors of IV treated mice showed the presence of mMSC-
GFP cells (Arrows).  All original magnification: 20X.  C) Examination of additional IV treated mouse 
intestinal sections identified no positive mMSC-GFP staining, nor in any region examined.  In contrast, 
examination of mesenteric tumor sections identified mMSC-GFP cells within the interior of the tumors 
(images 1-4) and along the periphery (4) (Arrows).  All original Mag 20X.  Similar levels of mMSC-
GFP cells were observed in IP injection tumor sections, and again, no MSCs were ever observed in IP 
mouse intestine samples.  Representative images are shown. D) Bioplex analysis of mouse and human 
soluble inflammatory cytokines in PLF identified significant alterations in the tumor microenvironment 
at 24 hrs.  All units are pg/mL (mean +/- SEM). E) Differential cell population analysis at 24 hrs post 
MSC administration displayed as percentages cells within the PLF, and as total cell number, as 
determined by three independent counts averaged per group (mean +/-SEM).  n=5 control, 5 MSC IV, 
and 5 MSC IP animals.  Significance, determined by ANOVA with a Fishers LSD post test, using 
comparison to saline control is indicated as p≤0.05=*, p≤0.01=**.   
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Supplemental Figure 3.  TRAIL-expressing mMSCs alter the soluble cytokines of the tumor 
microenvironment and induce apoptosis, but have no effect on tumor growth when administered 
intraperitoneally to mature tumors.  
A) Schematic of MSC cell therapy experiment protocol. B) Average sum tumor burden and the 
distribution of sum tumor burden on a per mouse basis are indicated (mean +/-SEM). C) Differential cell 
populations from within the PLF are presented as percentages of cells within the population, and total 
cell number in PLF (mean +/-SEM). D) Bioplex analysis of soluble inflammatory cytokines within PLF 
of mice therapeutically treated with mMSCs identified significant reductions in D) mouse and E) human 
soluble cytokines.  All units are pg/mL (mean +/-SEM); histogram colors: Saline control: White, 
mMSC-Alone: Light Grey, mMSC-Vector: Dark Grey, mMSC-TRAIL: Black.  F) Representative 
images demonstrating positive TUNEL staining of large numbers of tumor cells (yellow-brown) 
following administration of either mMSC-Alone or mMSC-TRAIL, compared to control. Original 
magnification 20X, scale bar indicates 200μm.  n=5 Saline control, 7 mMSC-Alone, 8 mMSC-Vector, 
and 6 mMSC-TRAIL.  Significance as determined by ANOVA with a Fishers LSD post test is indicated 
as p≤0.05=*, p≤0.01=**, p≤0.001=*** with respect to Saline levels.  Significant changes between 
mMSC-TRAIL treatment and mMSC-Alone or mMSC-Vector are indicated by the symbols # and @ 
respectively, and significance is indicated as p≤0.05 level only.  The addition of p-values approaching 
significance in the figure represent comparison to Saline controls only. 
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Supplemental Methods: 
Cell culture  
  Murine Mesenchymal Stromal Cells (mMSCs) at passage 3 and 5 were obtained from the Texas 
A&M Stem Cell Core facility.  These cells have previously been extensively characterized for cell 
surface marker expression and differentiation capacity.  Bone marrow MSCs from C57Bl/6J (mMSC) 
and C57BL/6-Tg(UBC-GFP)30Scha/J mice (GFP-mMSCs) were purchased. Cells were expanded in 
culture using mMSC media: Isocove’s Modification of Dulbecco’s Medium (IMDM) (Gibco, Life 
Technologies Grand Isle, NY), 10% Horse Serum (Hyclone, Rockford, IL), 10% fetal bovine serum 
(FBS) (Hyclone, Rockford, IL), 50 U/ml penicillin G/50 µg/ml streptomycin sulfate (1%) (Pen/Strep) 
(Invitrogen, Life Technologies Grand Isle, NY), 2mM L-glutamine (1X) (L-Glut) (Invitrogen, Life 
Technologies Grand Isle, NY), and used at passages 7-8.  Cells were trypsinized for injection using 
2.5% Trypsin/EDTA (Invitrogen, Life Technologies Grand Isle, NY), counted using a hemacytometer, 
and re-suspended in 1X phosphate-buffered saline (PBS), to a final concentration of 1x10
6 cells per 
300µl.  An aliquot of the same PBS was made for injection of control mice.  mMSCs at passage 3 were 
cultured as described above, and used for stable transfection and G418 clonal selection and expansion of 
hTRAIL plasmid (Truclone plasmid SC126304, Origene) 
  Human Mesenchymal Stromal Cells (hMSCs) at passage 5 were obtained from the Texas A&M 
Stem Cell Core facility. Bone marrow human MSCs (hMSC) were expanded and lentivirus transduced 
with green fluorescent protein (GFP).  All human MSCs used in the in vitro experiments described here 
expressed cytoplasmic GFP.  Cells were expanded in culture using hMSC media: Modification of Eagle 
Medium-Earls Balanced Salt Solution (MEM-EBSS) (Hyclone), 20% FBS, 1% Pen/Strep, 2mM L-Glut, 
and used at passages 7-8.  Cells were expanded, and trypsinized for injections as described above. 
  Human bone marrow MSCs which were transduced with TRAIL were provided to Dr. Sam Janes 
by Dr Mark Lowdell (Paul O'Gorman Laboratory of Cellular Therapeutics, Royal Free Hospital, MSCs Expressing TRAIL Inhibit Malignant Mesothelioma 
London, UK), and were cultured as described for hMSCs above.  MSCs transduced with a Tet-on 
plasmid had FBS replaced with Tet-system approved FBS (Clontech, Paris, France). 
  A549 cells are available commercially from ATCC, and were cultured in MM media: Dulbecco’s 
Modified Eagle Medium: Hams F-12 (DMEM:F12) 50:50 mix (Hyclone, Rockford, IL), 10% FBS, 1% 
Pen/Strep, 2mM L-Glut. Cells were grown until 80% confluent, lifted as described previously and 
pelleted for RNA isolation.  
  Jurkat cells are available commercially from ATCC and were cultured in RPMI, 5% FBS, 1X 
Pen/Strep, 2mM L-glut, 2500mg/ml Glucose, 1mg/ml Folate in 2g/L Sodium Bicarbonate, 1mM Sodium 
Pyruvate, and 50µM Beta-mercaptoethanol. Cells were cultured and treated with recombinant human 
TRAIL protein as the positive control for apoptosis induction.  
 
MM cell lines 
  Human pleural mesothelioma cell lines Hmeso and PPM Mills were provided by the Mossman 
lab.  The Hmeso cell line was previously described (2) and obtained from Dr. Joseph Testa (Fox Chase 
Cancer Center, Philadelphia PA).  The PPM Mill line (H2373) was previously isolated by Dr. Harvey 
Pass, (NYU Langone Medical Center) (2).  Cells were expanded in culture using MM media + HITS: 
Cells were expanded in culture using MM medium consisting of Dulbecco’s Modified Eagle Medium: 
Hams F-12 (DMEM:F12) 50:50 mix (Hyclone, Rockford, IL), 10% fetal bovine serum (FBS) (Hyclone), 
50U/mL penicillin G/50µg/mL streptomycin sulfate (1%) (Pen/Strep) (Invitrogen, Grand Isle, NY), 
2mM L-glutamine (L-Glut) (Invitrogen), and 0.1µg/mL hydrocortisone, 2.5µg/mL insulin, 2.5µg/mL 
transferrin, 2.5ng/mL sodium selenite (HITS) (Sigma Aldrich, St. Louis, MO). 
  Human peritoneal MM cell lines HAY, YOU, ROB, ORT, PET, PRO, and HEC cell were 
isolated by Dr. Claire Verschraegen (The University of New Mexico Health Science Center - Cancer 
Research and Treatment Center), were previously described (28), and were generously provided by the MSCs Expressing TRAIL Inhibit Malignant Mesothelioma 
Verschraegen lab.  Human pleural MM cell lines CRL-5820 and CRL-5915 are commercially available 
cell lines from American Type Culture Collection (ATCC), described further in Toyooka (31), and 
generously provided from the Janes Lab.  These nine cell lines were cultured using MM media.  
 
Co-culture of MM cells and MSCs 
  MM cell lines and MSC cell lines were trypsinized off of the plate using 2.5% Trypsin/EDTA 
(Invitrogen), counted using a hemacytometer, and were plated in each media (hMSC media, mMSC 
media, MM media and MM media +HITS) alone to determine viability.  Adherence to tissue culture 
dishes at 24 hrs and proliferation by 72 hrs was considered viable.   MSC cells are adherent and viable in 
MM media and MM media +HITS, and all MM cell lines were adherent and viable in hMSC media, 
however 6 of the 11 MM cell lines were not adherent in mMSC media.  The non-adherent cells were 
examined for viability using trypan blue exclusion, and cell count on hemacytometer, which determined 
that the MM cells were still live, but not proliferating in the mMSC media, as a loss of cell number 
relative to the initial plated count was always observed. Therefore further in vitro experiments were 
performed in either MM media or MM Media +HITS as determined by the MM cell line in use.    
  GFP-mMSCs were plated at an equal number with Hmeso cells in the same well of a 6-well dish 
using MM media +HITS, and examined by light and fluorescence microscopy on day 2 for adherence to 
confirm that both cell lines would adhere for co-culture analysis.  Hmeso and GFP-mMSC or hMSCs 
co-cultures were allowed to grow until day 7 and the all cells were examined for proliferation by 
microscopy, and by flow cytometry gated for GFP.  Flow cytometric analysis of these populations for 
the overall ratio of MSC to Hmeso cell numbers revealed that the cells maintain the ratio that they were 
plated at (data not shown), and that this held true for both mouse and human MSCs.   
 
 MSCs Expressing TRAIL Inhibit Malignant Mesothelioma 
hTRAIL transfection, transduction, and induction 
  Mouse bone marrow-derived MSCs were transfected as follows: the hTRAIL cDNA clone for 
hTRAIL (Trueclone, Cat no. SC126304, OriGene Technologies, Rockville MD) in the vector pCMV6-
XL5, was transfected into mMSCs at passage 3 using OptiMEM® (Gibco) and Lipofectamine LTX Plus 
kit (Invitrogen) following manufacturers recommended protocols.  Empty vector transfection was used 
to generate mMSC-Vector control cells.  After transfection cells were selected using 300ng/ml G418 
(Sigma Aldrich) in media changed every 2 days until colonies were beginning to form.  Cells were then 
passaged into 96-well plates, at a confluence of one cell per well, and maintained in selection for 2 wks, 
with only one further passage before RNA (qPCR for hTRAIL mRNA levels) and protein (flow 
cytometry for surface expression) analysis of constitutive hTRAIL expression and generation of frozen 
stocks (50% FBS, 45% Media, 5%DMSO). 
  Human MSCs were transduced with the TRAIL-IRES-eGFP Lentivirus vector (FLT) as 
previously described (22).   The TRAIL-IRES-eGFP lentivirus vector (previously described by 
Loebinger  (21, 22) was produced using a lentiviral plasmid (pRRL-cPPT-hPGK-mcs-WPRE) in which 
Tet-On system elements had been introduced (generously provided by O. Danos, University College 
London), and was then used as a backbone for the incorporation of TRAIL DNA. The existing reporter 
gene, MuSEAP, was excised using the MluI and EcoRV restriction sites. The IRES-eGFP sequence 
(from pENTR1A) was amplified, and restriction sites were introduced by PCR and then inserted into the 
plasmid in place of MuSEAP. Subsequently, human TRAIL (amino acids 1-281; RZPD) was similarly 
amplified and restriction sites were introduced by PCR and then cloned into the lentivirus plasmid, via 
MluI and BstB1 restriction sites, next to the IRES-eGFP. The plasmid constructs were confirmed by 
DNA sequence analysis (Cogenics). 
  The lentivirus was produced by transfecting 293T cells with 15 mL Opti-Mem, plus 10 mL of a 
solution made by mixing 3.6 mL polyethylenimine (Sigma-Aldrich) and 56.4 mL Opti-Mem to 600 Ag MSCs Expressing TRAIL Inhibit Malignant Mesothelioma 
TRAIL plasmid, 450 Ag of the packaging construct pCMV-dR8.74, 150 Ag of a plasmid producing the 
VSV-G envelope, pMD.G2, and 60 mL Opti-Mem (both pCMV-dR8.74 and pMD.G2 were a kind gift 
from A. Thrasher, University College London). The lentivirus was concentrated by ultracentrifugation at 
18,000 rpm (SW28 rotor, Optima LE80K Ultracentrifuge, Beckman), at 4°C and stored at -80°C before 
use.  Human MSCs were transduced with a 10-fold multiplicity of infection with 4 Ag/mL polybrene 
(Sigma-Aldrich), and successful transduction was confirmed by transgene activation.  hTRAIL 
expression was induced by treatment of cells with 10µg/ml Doxycycline (DOX) (Sigma Aldrich, Stock 
10mg/ml).  Cells were treated with DOX every 24 hrs for 3 days, and the surface expression of TRAIL 
was determined by  flow cytometry as described below. TRAIL protein production was further 
confirmed by ELISA (R&D Systems) according to manufacturer's instructions.  Transduced cells were 
labeled as hMSC-containing full length TRAIL (hMSC-FLT).  FLT transduced hMSC’s, once DOX 
stimulated, were labeled as hMSC-TRAIL.  FLT transduced hMSCs that were unstimulated were vector 
controls (hMSC-Vector), and untransduced hMSCs (hMSC-Alone) were used as controls.   
 
Cell Surface Expression of hTRAIL 
  Mouse MSC-TRAIL clones 49 and 87, and human MSC-FLT cells +DOX, were trypsinized off 
the plate and resuspended in 300µl of 1X phosphate buffered saline (PBS).  Samples were fixed for 1 hr 
in 4% paraformaldehyde (PFA), spun down and resuspended in 1 X PBS, 2% FBS (Flow Buffer (FB)).  
Cells were washed once in 500µl of FB, with the supernatant poured off at each step. Cells were stained 
with 1° antibody anti-hTRAIL (ab#2056 Rabbit polyclonal – Abcam, Cambridge, MA) in 200µl of a 
1:50 dilution, and incubated at RT for 1hr. Cells were washed 2x in 500µl FB.  Cells were stained with 
2° antibody Goat anti Rabbit IgG Alexa 647 (Invitrogen, Life Technologies, Grand Isle, NY) in 200µl of 
a 1:500 dilution, and incubated, covered, at RT for 30 min. Cells were washed 2x in 500ul FB and MSCs Expressing TRAIL Inhibit Malignant Mesothelioma 
resuspended in 300µl for flow cytometry analysis.  An unstained and secondary-only control tube was 
also stained for each cell line examined.   
 
Apoptosis detection  
  MM cell lines Hmeso and YOU were plated into two six well dished each (50,000 cells per test 
well 100,000 control well), and allowed to adhere overnight.  An extra well was plated on a separate six 
well dish for compensation controls.  MSC cell lines were trypsinized as previously described and 
counted, and stained in 25uM Cell Tracker Blue –CMAC (Invitrogen, Life Technologies, Grand Isle, 
NY) for 30 min at 37°C, then cells were spun, and fresh media was placed on the cells, followed by 
incubation for 30 min at 37°C.  Media was changed on the MM cells to remove dead cells caused by 
plating (2 ml per well).  MSCs (25,000 cells) were seeded onto the test wells containing MM cells, and 
allowed direct coculture for 24 hrs.  In an additional well of the compensation controls plate 1 x 10
5 Cell 
Tracker stained hMSCs were seeded.  In a 3ml flow cytometry tube, the media was collected for every 
well, and wells were washed in 500µl of 1X PBS, which was saved and placed in the corresponding 
tube.  Cells were trypsinized with 300µl if Trypsin as previously described, stopped with 1ml of media, 
and washed thoroughly before collection into the same test tube as the media and wash.  All cells were 
then pelleted by centrifugation in the swinging bucket rotor, at 1200 rpm for 5 minutes at RT.   
  Cells were stained for early, mid and late apoptosis using the Annexin V PE Apoptosis Detection 
Kit (eBioscience, San Diego, CA).  Cells were washed once in 500µl FB, and once in 500µl 1X Annexin 
Binding Buffer (ABB) (diluted from 10X stock in the kit with dH2O).  Supernatant was poured off and 
cells were resuspended in the remaining buffer (~ 100µl).  Cells were stained with PE conjugated anti-
Annexin V (5µl per sample in 100µl 1X ABB), covered, for 15 min at RT.  Cells were washed 2x with 
500µl of 1X ABB, and resuspended in the residual buffer after pour off.  Cells were stained for viability 
using 7-AAD Viability Staining Solution provided (5µl per sample in 300µl 1X ABB), and cells were MSCs Expressing TRAIL Inhibit Malignant Mesothelioma 
examined by flow cytometry within 4 hours.  Single color compensation controls were generated for 
each stain; MM cells were trypsinized and placed into three tubes, unmodified for unstained, cells fixed 
for 15 min with 4% PFA for the Annexin V- PE, or fixed 30 min with 4% PFA for 7-AAD Viability 
stain, and Cell Tracker blue labeled hMSC were trypsinized to a separate tube for the compensation 
controls.    Flow cytometry was performed on a BD LSRII (BD, Franklin Lakes, NJ) following standard 
protocols, with the exchange of the 610 filter to the 670 filter for reduced overlap of the PE and 7-AAD 
fluorescence spectra.   
Terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL)  assay was used 
to assess tumor cellular apoptosis. Briefly, formalin fixed and paraffin-embedded tissue sections were 
deparaffinized, hydrated and antigen retrieval was carried out by incubating tissue with Dako target 
retrieval solution (Dako, Inc, S1699). TUNEL reaction mixture was applied according to manufacturer’s 
instruction (Roche, Inc, 11684817910). For negative controls the transferase enzyme was omitted. The 
fragmented DNA is stained brown, while DNA without damage is stained blue as a result of 
counterstaining with hematoxylin. 
 
Cell differentiation and staining: 
  Stem cells were trypsinized as described previously following exposure to MM cell line medias, 
and MM cell lines, or after expansion of TRAIL expressing clones, and seeded 60,000 per well into a six 
well dish per cell line/condition, and allowed to adhere overnight. Cells were changed into 
differentiation media or control media the following day and cultured for three weeks, with media 
changed two times a week.  Osteocyte differentiation media (ODM) and Adipocyte differentiation media 
(ADM) have been previously described by the Texas A&M Stem Cell Core.  Cells were washed in PBS 
and fixed in 10% formalin for 20 min at RT. Adipose differentiation was washed in PBS the stained 
with Oil-Red O, Osteogenic differentiation was washed in water, and stained with Alizarin Red, and MSCs Expressing TRAIL Inhibit Malignant Mesothelioma 
stained for 20 min at RT.  Wells were washed in the respective buffers until supernatant was clear, and 
cells were examined for the presence of adipocytes and osteocytes by microscopy.  Images were 
captured using an Olympus BX50 upright light microscope (Olympus America, Lake Success, NY) with 
an attached Q Imaging Retiga 2000R digital CCD camera (Advanced Imaging Concepts, Inc., Princeton, 
NJ). 
 
 
In Vitro Analysis of Tumorogenicity 
MM cell lines and MSC cell lines were trypsinized using 2.5% Trypsin/EDTA (Invitrogen), and counted 
using a TC20™ Automated Cell Counter (BioRad, Hurcules, CA).  Cells were plated as described below 
in their own media, and allowed to adhere overnight before a media change and placing of the transwell 
inserts to initiate interaction. 
 Proliferation  assay:  MM cells were plated in 24 well chambers, 2,000 cells per well.  An extra 
six well dish was plated with 1 x 10
6 cells per well for cell number standard curve.  MSCs were plated in 
24 well Transwell inserts 0.4 µm pore size, at 1000 cell per insert (Corning Incorporate, Corning, NY).  
After 24 hours, plating media was removed by aspiration, experimental media was added (MM cell line 
specific), and Transwells containing stem cells were placed in the 24 well dish containing MM cells; this 
is day 0.  On the experimental day to be analyzed, (4-7), Transwells were removed and media aspirated, 
MM cells were trypsinized in 150 µl of trypsin, stopped with 200µl of media.  Wells were washed 
thoroughly and 100µl was plated in triplicate in a 96 well flat bottom plate. Cells were allowed to settle 
to the bottom of the plate for 30 min at 37°C.  One well of additional MM cells for the ladder was 
trypsinized and counted on BioRad hemacytometer.  200,000 cells in 200µl of media were placed in the 
first ladder well, and using serial 1:2 dilutions of 100 µl, a ladder from 100,000 to 1,563 cells in 100µl 
was generated, with empty media control wells. Using the CyQuant Proliferation Assay (Invitrogen), MSCs Expressing TRAIL Inhibit Malignant Mesothelioma 
green nucleic acid staining solution was mixed (0.4µl stain, 2.0µl suppressor, in 97.6µl 1x PBS) and 
100µl was added to experimental and ladder wells, and incubated at 37°C for 1hr.  Live MM cell 
number was determined using a bottom plate read using a 480/535nm fluorescence reader, with 
sensitivity set at 60. Fresh ladders were made for every daily plate read using the MM cell line being 
examined.  
 Migration  assays: Exposure- MM cell lines were plated 25,000 cells in each well of a six well 
dish, and allowed to adhere overnight.  15,000 MSC cells were plated in a 6 well transwell chamber 
insert (0.4µm pore size, Corning Incorporate, Corning, NY), in their own media above and below the 
membrane and allowed to adhere overnight.  Transwell inserts were suspended above the MM cells 
following a media change in both plates to the MM media at the maximum volume in both chambers, 
with care taken to aspirate media from the external surface of the transwell, this was day 0.  Following 5 
days of transwell culture without media change, MM cells were trypsinized as described previously, 
with an additional wash and change into serum free media, and counted on BioRad hemacytometer.  
Effect- 30,000 MM cells were plated in triplicate into the upper chamber of a 24 well transwell (8.0µm 
pore size) and placed above MM media containing 20% FBS.  Cells were allowed to migrate through the 
membrane for 24 hrs.  Cells remaining on the inside of the Transwell were removed with a sterile cotton 
swab, and the Transwell was fixed in ice cold methanol for 10 minutes. Transwells were then stained in 
0.01% Crytsal Violet in 20% Ethanol for 10 minutes.  The Transwell was washed three times in dH2O, 
and stained cells were lysed in 320µl of 5% methanol, 5% acetic acid in dH2O.  Three 100µl aliquots 
were plated in a flat bottomed 96 well plate and OD595 was read by plate reader. One transwell with no 
cells was used as a negative staining control, to normalize all OD readings.   
 Invasion  assay: MM cells were plated as described for the Exposure segment of the migration 
studies above.  On day four of exposure invasion transwells were prepared.  Transwell inserts (24 well, 
8.0µm pore) were coated with 100µl of BD Matrigel – Basement membrane matrix (cat no.354234 - BD MSCs Expressing TRAIL Inhibit Malignant Mesothelioma 
Biosciences, Franklin Lakes, NJ) in serum free media at a 1:20 dilution, and allowed to air dry 
overnight.  Effect-  100,000 MM cells were plated in serum free media into the prepared invasion 
transwells, and placed above MM media containing 20% FBS.  After 24 hours invading cells adherent to 
the underside of the transwell inserts were fixed and stained as described above, and readings taken at 
OD595.  
  Anchorage Independent Growth:  MM cell lines were examined for anchorage independent 
growth using the Cytoselect™ 96 well Cell Transformation Assay (Cell Biolabs, Inc. San Diego, CA) 
following the manufacturers protocol with the following modifications.  The lower agar layer was 
prepared as written, plated and allowed to set at 4°C for 30 min.  Cell lines were trypsinized and counted 
as described previously, then resuspended at 1 x 10
6 cells per ml.  Cell mixtures were aliquoted into test 
tubes at a maximum volume of 25µl in media (enough for 5 wells), and incubated at 37°C for 30 
minutes. The cell agar layer was prepared as described without the cell addition, then 350µl was 
aliquoted into the cell mixture tubes. Cell agar layers were incubated for 10 min at 37°C.  The warm cell 
agar layer was plated in triplicate (75µl) onto the base agar layer and incubated at 4°C, methods then 
proceeded as written in the protocol.   Control wells of MM cells alone were plated at an equal number 
of cells as the number of MM cells within the cell mixtures, MSC cells alone were plated the same.  
 
SCID Mouse Xenograft Model of Human Malignant Mesothelioma 
    All animal procedures were approved by the UVM IACUC and conformed to all appropriate 
institutional and AAALAC standards.  A previously established model of intraperitoneal inoculation of 
human Hmeso cells into SCID mice was utilized (2).    In brief, for both the MSC localization to tumor 
and early tumor development models, 5 x 10
6 Hmeso cells (in 150μl sterile 0.9% NaCl [pH 7.4]) were 
injected IP into male, 6 week old Fox Chase SCID mice from Charles River Laboratories (Strain number 
236).  Injections were administered to the lower left anterior of the mice (1 injection site/mouse).  An MSCs Expressing TRAIL Inhibit Malignant Mesothelioma 
extra aliquot of Hmeso cells was replated in a 25 cm
2 culture flask after injections to verify cell viability. 
Ear punches were administered as needed to distinguish between animals.  All animal procedures were 
approved by the IACUC committee at UVM. Both free-floating spheroid and mesenchymal tumors 
lining the diaphragm were observed at 28 days in all mice at which time saline (n=5), or 1 x 10
6 MSC 
cells in 500 µl sterile 0.9% NaCl (pH 7.4) were injected either systemically (intraveinous – tail vein [IV] 
(n=5)) and locally (intraperitoneal [IP] (n=5)), for 24 hr for the localization analysis (Figure 2), or MSCs 
as described were administered IP on Day 7 and Day 14 of tumor development (n=8; saline n=7), with 
tumor burden measured on day 28, for the early tumor development model (Figure 3). 
  MSCs as a cell based therapy experiments used a modification of the above model, to allow a greater 
therapeutic window.  In brief, 1 x 10
6 Hmeso cells (in 150 μl sterile 0.9% NaCl [pH 7.4]) were injected 
into SCID mice as described above.  Mesenchymal tumors throughout the IP cavity were observed by 28 
days in all mice.  Mice were treated by IP injection with either 1x PBS, or 3 x 10
5 MSC cells in 300µl 
sterile 1x PBS, beginning on day 21, and receiving two injections per week for three weeks (Figure 5 
and Supplemental Figure 2).  Mice received either control injections of saline (n=6), MSC-Alone 
(unmodified mMSC or hMSCs (n=8 each)); MSC-Vector cells (mMSCs transfected with empty vector 
pCMV6-XL5 (n=8), or hMSC-FLT cells not stimulated with DOX (n=8)); or MSC-TRAIL cells 
(mMSC-TRAIL clone 87 (n=8), or hMSC FLT cells stimulated for 72hr with DOX (n=8)). Tumor 
burden assessment was performed on day 46 of tumor growth.  To correct for any cell growth 
differences, hMSC-FLT cells were grown for simultaneous Vector and TRAIL injection, and in each 
plating, half of the cells would receive DOX treatment.  MSC origin is indicated by a preceding lower 
case m (mouse) or h (human).  Tumor burden assessment was performed on day 46, and was determined 
by collection of all tumors, including any small metastatic nodes, with detailed examination of pleural 
cavity, diaphragm, liver, stomach, spleen, intestines, kidney, reproductive organs, and subcutaneous area 
proximal to MM injection site for metastasis, with weight and volume recorded for all tumors.  No MSCs Expressing TRAIL Inhibit Malignant Mesothelioma 
difference was observed when comparing weight and volume data, thus weight is depicted.  Tumors 
were defined as either spheroid: free floating within the peritoneal cavity; or mesenteric: attached to the 
mesentery.  Day 46 spheroid tumors were never observed.   
 
 
 
Assessment of peritoneal inflammation 
  Mice were euthanized with 0.1ml of Sleep Away (26% sodium pentobarbital, Webster 
Veterinary), and peritoneal lavage fluid (PLF) was collected as previously described (2, 32).   3ml of 
cold 1X PBS was instilled into the peritoneal cavity of each mouse using an 18g needle. The abdomen 
was then lightly massaged, and the PBS removed.  Recovered volume was recorded, and samples were 
centrifuged to pellet cells.  The supernatants were collected and soluble inflammatory cytokine levels 
were assayed in PLF and cell culture media supernatants using Bio-plex Pro™ Mouse Cytokine 23-plex 
Assay and Bio-plex Pro™ Human Cytokine 27-plex Assay (BioRad), using manufacturers 
recommended protocol.  Cell pellets were treated with 3ml ACK Lysis buffer (Gibco) for 30 sec to 
remove red blood cells, and lysis was halted by addition of 8ml 1X PBS.  Cells were pelleted and re-
suspended in 600µl 1X PBS and the total white blood cell counts in PLF were assessed using an 
ADVIA® Hematology Analyzer (Siemens Diagnostics, Johnson City, TN).  Cytospins were prepared 
from 5x10
5 cells following standard protocols (30).  Cytospins were stained using a HEMA 3 kit (Fisher 
Scientific, Middletown, VA) per the manufacturer’s directions.   
 
Immunofluorescence microscopy detection of GFP-MSCs 
 Immunofluoresence  visualization of the GFP-Alexa-555 antibody was performed on sections of 
paraffin-embedded Mesenteric Hmeso tumors derived from 2 IV-injected mice, 2 IP-injected mice and 2 MSCs Expressing TRAIL Inhibit Malignant Mesothelioma 
Saline control mice. Sections were deparaffinized in xylenes followed by hydration in dH2O via 
decreasing alcohol concentrations.  Antigen retrieval was performed by placing slides in 1X Dako target 
retrieval solution at 98-99°C for 20min (Dako, Carpinteria, CA).  Slides were then cooled to room 
temperature before auto-fluoresence was blocked with 10% bovine serum albumin BSA (Sigma) in 1X 
PBS for 10min.  Sections were incubated for 15 min in 0.1% Triton-X (Sigma) in 1% BSA, 1X PBS 
solution, followed by two 5min washed in 1X PBS.  Mouse anti-GFP-Alexa-555 antibody (Invitrogen) 
was diluted 1:200 in 1% BSA (Sigma) in 1X PBS. Tumor sections were treated with diluted primary 
antibody overnight in a humidified chamber at 4°C.  A 1:10,000 dilution of DAPI nucleic acid stain 
(Molecular Probes, Life Technologies, Grand Isle, NY) in 1X PBS was then applied to each section for 
5min.  Slides were washed with 1X PBS before adherence of coverslips (Aqua Poly/Mount, 
Polysciences Inc., Warrington, PA), and stored at 4°C.  Confocal images of 2-3 fields per tumor or 
intestine were acquired using a 40X objective lens on a BioRad MRC 1024ES confocal scanning laser 
microscope running BioRad Lasersharp 2000 imaging software (Advanced Imaging Concepts, Inc.). A 
triple fluorescence mode was used to visualize cell nuclei (blue) and GFP fluorescence (green – not 
shown in confocal images) and Anti-GFP Alexa-555 (red) in tissues. Images were scanned in sequential 
mode to avoid bleed- through between channels. Images were acquired sequentially then were pseudo 
colored and merged. 
 
RNA isolation, cDNA conversion, qPCR 
  RNA was isolated from A549, mMSC, and mMSC-TRAIL cells by Trizol (Invitrogen), 
converted to cDNA using BioRad iScript cDNA synthesis kit (BioRad, Hercules, CA), and quantified 
using IQ SyberGreen (BioRad), per manufacturers recommended protocol.  Cells were trypsinized as 
described above and pelleted, supernatant was removed, and pellet resuspended in a small volume.  
500µl of Trizol (Invitrogen, Life Technologies, Grand Island, NY) was added and mixed.  100µl of 1-MSCs Expressing TRAIL Inhibit Malignant Mesothelioma 
bromo-3-chloropropane (BCP) (Molecular Research Center, Cincinnati, OH) was added to each tube, 
and the sample was vortexed.  Tubes were spun for 5 minutes at 12 thousand RPM in a fixed angel rotor.  
Aqueous phase was isolated into a new tube without dislodging protein fraction layer. Saturated 
ammonium chloride (25µl) was added to the tube to facilitate RNA precipitation, and 500µl of 
isopropanol, Samples were mixed and incubated for 20 min at -20°C. Samples were spun to pellet RNA, 
supernatant aspirated, and washed 1x in 70% ethanol. RNA pellet was air dried for 5-10 minutes but not 
completely dried, and sample was resuspended in 40µl of Rnase Free dH2O.  Concentration was 
dertermined by Nanodrop.   
  RNA was converted to cDNA using BioRad iScript cDNA synthesis kit (BioRad, Hercules, CA) 
following manufacturers recommended protocol, using 800ng of RNA per 20µl reaction.  IQ 
SyberGreen (BioRad, Hercules, CA) qPCR amplification of human TRAIL mRNA was performed in 
25µl reactions following recommended protocols on 10µg of converted cDNA (calculated) using the 
following primers hTRAIL- F 5’-TTTCGGGGCCTTTTTAGTTGG-3’, R 5’-
ACTTGAGAGATGGATTGTTGC-3’, and GapdH F 5’-ACGACCCCTTCATTGACCTC -3’, R 5’-
TTCACACCCATCACAAACAT -3’.  Control RNA was isolated from an abundance of A549 cells, 
aliquots were used as a cDNA conversion efficiency control and on converted sample 2µg in 40µl was 
used subsequently to generate a cDNA ladder which was run for primer efficiency on every plate.  
Comparisons between plates were normalized to the ladder.   PCR was run with standard conditions and 
an annealing temperature set at 56°C, with 10s, 15s, and 20s times for denaturing, annealing, and 
extension respectively.  Melt curve from 40-95°C was used to examine amplicon purity.    
 
Statistical analysis 
  All data were evaluated by analysis of variance (ANOVA) using the Fishers LSD procedure for 
adjustment of multiple comparisons to the Saline treatment groups. Where appropriate Students T-test MSCs Expressing TRAIL Inhibit Malignant Mesothelioma 
using Welch’s correction was used (33).  Statistical significance was determined as p≤0.05= single, 
p≤0.01= double, p≤0.001= triple symbols.  Significance of any treatments compared to Saline controls is 
indicated by *, significance between MSC-TRAIL cells and other MSC cell controls is indicated by # 
and @ at the p≤0.05 level.  Any p-values approaching significance noted in the figures are in reference 
to comparisons with Saline controls only.  